Skip to content

CORPharmaceutical distribution and specialty services

Cencora

By

Updated

Not investment advice. Kevin may own this stock. How we value stocks

History
Price
$339.09
Discount category
Close to intrinsic value
Analysts
Bullish
Next earnings
Feb 3 · · estimated
Pick status
Research only

In short

Thesis
Cencora trades close to its intrinsic value because investors pay a full price for its steady growth but weigh opioid settlements and debt, and specialty growth as guided can lift the value.
Gap
Can close. The Q1 fiscal 2027 report in early February 2027 and the MWI merger, planned to close by March 31, 2027, show whether the guided growth holds.

Company guidance: Adjusted diluted EPS of $19.40 to $19.75 and revenue growth of 3% to 5% for fiscal 2027 (, Fiscal 2026 earnings release (8-K))

Price history

About

Cencora is one of the largest distributors of medicines in the United States. It buys medicines from manufacturers and delivers them to pharmacies, hospitals, health systems and physician practices. It also owns management services organizations for physician groups in oncology (OneOncology, bought in February 2026) and retina care (Retina Consultants of America), and it gives logistics and other services to drug makers.

From October 1, 2026, it reports two segments: Pharmaceutical Distribution and Services, with revenue of $284.5 billion and operating income of $2.7 billion in fiscal 2026, and Specialty Pharmaceutical and Provider Services, with revenue of $45.4 billion and operating income of $1.7 billion. Total revenue was $337.4 billion in fiscal 2026. Its fiscal year ends on September 30.

The shares trade on the New York Stock Exchange. The head office is in Conshohocken, Pennsylvania. Robert P. Mauch is President and Chief Executive Officer.

Thesis

Cencora trades close to its intrinsic value because investors pay a full price for its steady growth in drug distribution and specialty services, but they weigh the opioid settlements, the debt from its purchases of physician groups and the loss of some Walgreens volume. In fiscal 2026, adjusted diluted EPS rose 12.3% to $17.97, and Cencora expects $19.40 to $19.75 for fiscal 2027. For the value to rise, three things must be true. Operating income of the specialty segment, which includes the oncology and retina groups, must grow by 18% to 21% in fiscal 2027, as guided.

The sale of Profarma and the merger of MWI Animal Health with Covetrus must close as planned; the guidance assumes March 31, 2027 for MWI. Changes to drug prices in the United States must not cut the fees that Cencora earns from manufacturers. The Q1 fiscal 2027 report, expected in early February 2027, is the next test. Lower margins or new opioid claims can keep the value flat.

Checkpoints

  1. Nov 4, 2026Passed
    Fiscal 2026 results and fiscal 2027 guidanceAdjusted diluted EPS at the high end of the guidance and EPS growth of 8% or more guided for fiscal 2027 pass; less fails.Outcome: Adjusted diluted EPS rose 12.3% to $17.97, and Cencora guided to $19.40 to $19.75 for fiscal 2027.
  2. Feb 3, 2027 · est.Pending
    Q1 fiscal 2027 resultsA confirmed or higher fiscal 2027 EPS guidance and growth in specialty operating income pass; a guidance cut fails.
  3. Mar 31, 2027 · est.Pending
    Closing of the MWI Animal Health merger with CovetrusClosing by March 31, 2027 with the planned cash proceeds passes; a delay or a lower price fails.

Every passed and failed checkpoint across all picks

Recent events

  • November 4, 2026Cencora reported fiscal 2026 results. Revenue rose 5.0% to $337.4 billion, GAAP diluted EPS was $17.95 and adjusted diluted EPS rose 12.3% to $17.97. For fiscal 2027, Cencora expects adjusted diluted EPS of $19.40 to $19.75 and adjusted free cash flow of about $3.5 billion. It introduced two new segments and raised the quarterly dividend by 10% to $0.66 per share.
  • October 21, 2026Cencora agreed to buy American Oncology Network, a network of more than 350 oncology providers in 21 states, at an enterprise value of $2.4 billion. Cencora expects to pay about $1.7 billion for a 75% interest if other holders keep 25%, and it expects the deal to add to adjusted diluted EPS in the second year after closing.
  • August 12, 2026Cencora said that some Walgreens volume outside the prime vendor agreement began to move to another supplier on July 1, 2026. The prime vendor agreement, which is most of the Walgreens business, did not change, and Cencora kept its fiscal 2026 guidance.
Show 2 older events
  • February 18, 2026Cencora agreed to merge MWI Animal Health with Covetrus. The deal values MWI at an enterprise value of $3.5 billion. Cencora will receive $1.25 billion in cash and $800 million of preferred equity, and keep 34.3% of the common equity of the combined company.
  • February 13, 2026Cencora issued $3.0 billion of senior notes, due from 2029 to 2056, to repay a term loan that paid for part of the purchase of OneOncology. The purchase closed on February 2, 2026.

Latest news and filings

Last earnings
November 4, 2026 (8-K on sec.gov)
Next earnings
Expected about February 3, 2027. The company has not confirmed the date.

Every filing on SEC EDGAR (CIK 1140859)

Risks

Bull case: Specialty segment income growth of 18% to 21% in fiscal 2027 and the new oncology networks can lift adjusted EPS to $19.40 to $19.75, from $17.97 in fiscal 2026.

  • A few customers give a large part of revenue, mainly Walgreens and a large mail order customer. A lost or changed contract can cut revenue and profit.
  • Cencora had an accrued litigation liability of $3,670 million at September 30, 2026, mainly for opioid settlements. Other opioid lawsuits continue, and their cost can be higher.
  • Changes to drug prices in the United States, such as lower list prices for brand medicines, can reduce the fees and margins of distributors.
  • GLP-1 medicines for diabetes and weight loss add revenue but have lower gross margins, so a larger share of them lowers the margin percentage.
  • The purchases of physician groups, such as OneOncology and American Oncology Network, add debt and can fail to give the planned profit.

Key statistics

Market cap
$65B
Shares of Jul 31, 2026
Dividend yield
0.8%
Current annual rate, at the price of Nov 21, 2026
P/E (trailing)
25.2
Price of Nov 21, 2026
EPS (trailing)
$13.47
12 months to Jun 30, 2026
52-week range
$244.82 – $377.54
To Nov 17, 2026
Beta
0.58
Vs S&P 500, 5 years monthly, to Oct 30, 2026
Average volume
1.3M
3 months, to Nov 17, 2026

Balance sheet

Cash
$4.9B
Debt
$11.3B
Net debt
$6.4B

Cash against debt

Cash$4.9B
Debt$11.3B

debt covered by cashnet debt $6.4B

When the debt is due

12 months$203M
Later$11.1B

Cencora funds itself mainly with payables to suppliers, bonds, term loans and cash flow. At September 30, 2026, cash and cash equivalents were $4,880 million, short-term debt $203 million and long-term debt $11,063 million.

Dividends

Dividend yield
0.8% (current annual rate, at today’s price of $339.09)
Paid per share
$2.46 in the last 12 months (4 payments)
Current annual rate
$2.64 ($0.66 × 4 a year)
Payout ratio
28% of the last fiscal year’s earnings (the year that ended September 30, 2025)
Latest ex-dividend date
November 13, 2026, $0.66 per share

Dividends per share by year

Cencora dividends per share by year
2016
$1.385
2017
$1.475
2018
$1.54
2019
$1.60
2020
$1.70
2021
$1.78
2022
$1.865
2023
$1.965
2024
$2.08
2025
$2.25

From 2020 to 2025, the dividend grew by about 5.8% a year. From 2016 to 2025, the dividend grew by about 5.5% a year.

Source: company filings and market data, read on November 18, 2026. The ex-dividend date is the first day a buyer no longer gets the next payment.

Questions about Cencora

What does Cencora do?

Cencora is one of the largest distributors of medicines in the United States. It buys medicines from manufacturers and delivers them to pharmacies, hospitals, health systems and physician practices. Its market cap is $65B at the current price of $339.09.

When does Cencora report earnings next?

This is an estimate: Cencora may report on February 3, 2027. It last reported results on November 4, 2026.

Is Cencora stock below its intrinsic value?

Cencora stock is close to intrinsic value. This is general information, not advice.

What changed recently at Cencora?

The latest update is from November 4, 2026. Cencora reported fiscal 2026 results.

What are the main risks for Cencora?

A few customers give a large part of revenue, mainly Walgreens and a large mail order customer. Cencora had an accrued litigation liability of $3,670 million at September 30, 2026, mainly for opioid settlements. Changes to drug prices in the United States, such as lower list prices for brand medicines, can reduce the fees and margins of distributors.

How much debt and cash does Cencora have?

At September 30, 2026, Cencora had $11.3B of debt and $4.9B of cash.

Does Cencora pay a dividend?

Yes. The current annual dividend of Cencora is $2.64 per share. That is a dividend yield of 0.8% at the current price of $339.09. In the last 12 months, it paid $2.46 per share (0.7%). The latest ex-dividend date was November 13, 2026.

Valuation against peers

CompanyP/E, last 4 quartersEV/EBITDA, last yearFree cash flow yield, last year10-year average P/E
CORCencora25.2x20.0x5.0%23.9x
CAHCardinal Health35.3xn/a7.2%33.9x
APGAPi Groupn/an/a3.7%n/a
SYYSysco20.8xn/a5.0%28.2x
TMUST-Mobile US16.0xn/a10.3%30.3x
Peer median20.8xn/a6.1%n/a
  • COR trades at 25.2x earnings, 21% above the peer median of 20.8x.
  • Its free cash flow yield is 5.0%, 1.1 points below the peer median of 6.1%.
  • Against its own history, the P/E is 5% above its average of 23.9x over 9 profitable years.

The peers are the companies on this site most like COR. The multiples come from company filings and today's price, and P/E uses GAAP diluted EPS. Picks shows no analyst forecast: the only look ahead is a company's own EPS guidance, where it gives one. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.

Similar companies

  • CAHCardinal HealthShares: Regulation and courts, Weight-loss drugs
    Intrinsic value
    Close to intrinsic value
    Gap
    Slow
  • NVONovo NordiskShares: Weight-loss drugs, Regulation and courts
    Intrinsic value
    Close to intrinsic value
    Gap
    Can close
  • GSKGSKShares: Regulation and courts, High debt
    Intrinsic value
    Below intrinsic value
    Gap
    Slow
  • RHHBYRocheShares: Regulation and courts, Weight-loss drugs
    Intrinsic value
    Close to intrinsic value
    Gap
    Can close
  • SYYSyscoShares: High debt, Regulation and courts
    Intrinsic value
    Below intrinsic value
    Gap
    Can close

Loading your notes…

Read it all? Star COR or pass, then go on to the next one.